Should I buy or sell Cellectar Biosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLRB shares. View CLRB analyst ratings or view top-rated stocks .

What is Cellectar Biosciences' stock price target for 2024?

2 equities research analysts have issued 12-month target prices for Cellectar Biosciences' stock. Their CLRB share price targets range from $12.00 to $28.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 557.9% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts .

How have CLRB shares performed in 2024?

Cellectar Biosciences' stock was trading at $2.77 on January 1st, 2024. Since then, CLRB stock has increased by 9.7% and is now trading at $3.04. View the best growth stocks for 2024 here .

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,530,000 shares, an increase of 34.6% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 1.4 days. Approximately 8.7% of the company's stock are sold short. View Cellectar Biosciences' Short Interest .

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CLRB earnings forecast .

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences's stock reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM) , Zynga (ZNGA) , Quantum (QTM) , Baytex Energy (BTE) , Sherritt International (S) , Bombardier (BDRBF) , Bombardier, Inc. Class B (BBD.B) , Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM) .

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free CLRB Stock Alerts

$3.04

-0.17 (-5.30%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.01
▼
$3.21
50-Day Range: $3.04
▼
$4.24
52-Week Range: $1.33
▼
$4.45

Volume: 1.64 million shs
Average Volume: 1.71 million shs
Market Capitalization: $98.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

Get Cellectar Biosciences alerts:

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 557.9% Upside
$20.00 Price Target
Short Interest: Bearish
8.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.85) to ($0.58) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.60 out of 5 stars

Medical Sector

758th out of 918 stocks

Pharmaceutical Preparations Industry

332nd out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Cellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cellectar Biosciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.66% of the float of Cellectar Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Cellectar Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cellectar Biosciences has recently increased by 34.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cellectar Biosciences does not currently pay a dividend.
Dividend Growth
Cellectar Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLRB.

3.3

News and Social Media Coverage

News Sentiment
Cellectar Biosciences has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 1 article on an average week.
Search Interest
6 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Cellectar Biosciences is held by insiders.
Percentage Held by Institutions
Only 16.41% of the stock of Cellectar Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.85) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectar Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectar Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLRB Stock News Headlines

April 9, 2024 | americanbankingnews.com

Cellectar Biosciences (NASDAQ:CLRB) Shares Pass Above 50 Day Moving Average of $3.73

March 29, 2024 | markets.businessinsider.com

Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 29, 2024 | nz.finance.yahoo.com

Jeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th Birthday

March 29, 2024 | finance.yahoo.com

Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?

March 28, 2024 | finance.yahoo.com

Q4 2023 Cellectar Biosciences Inc Earnings Call

March 27, 2024 | investorplace.com

CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023

March 27, 2024 | msn.com

Cellectar Biosciences FY 2023 Earnings Preview

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | benzinga.com

Earnings Preview For Cellectar Biosciences

March 27, 2024 | globenewswire.com

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

March 20, 2024 | globenewswire.com

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

March 14, 2024 | globenewswire.com

Cellectar Biosciences to Present at the 36th Annual Roth Conference

March 4, 2024 | globenewswire.com

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

February 22, 2024 | benzinga.com

Cellectar Biosciences Stock (NASDAQ:CLRB), Short Interest Report

February 15, 2024 | money.usnews.com

Cellectar Biosciences Inc

February 12, 2024 | seekingalpha.com

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

February 7, 2024 | finance.yahoo.com

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 25, 2024 | finance.yahoo.com

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

January 23, 2024 | investing.com

Cellectar Biosciences Inc (CLRB)

January 22, 2024 | msn.com

Cellectar stock climbs 8% on results for CNS malignancy therapy

January 22, 2024 | finance.yahoo.com

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

January 16, 2024 | finance.yahoo.com

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

January 12, 2024 | finance.yahoo.com

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

January 8, 2024 | marketwatch.com

Cellectar Biosciences Shares Hit 52-Week High After Positive Iopofosine I Results

January 8, 2024 | msn.com

Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?

January 8, 2024 | marketwatch.com

Cellectar Biosciences' Iopofosine I Meets Primary Endpoint in Rare Blood Cancer Study

See More Headlines

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CLRB
CUSIP: N/A
CIK: 1279704
Web: www.cellectar.com
Phone: (608) 441-8120
Fax: 608-441-8121
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.00
High Stock Price Target: $28.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +557.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,821.29%
Return on Assets: -280.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.81
Quick Ratio: 0.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.36) per share
Price / Book: -8.44

Miscellaneous

Outstanding Shares: 32,260,000
Free Float: 30,777,000
Market Cap: $98.07 million
Optionable: Optionable
Beta: 0.92

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. James V. Caruso (Age 65)
President, CEO & Director
Comp: $846.48k
Mr. Chad J. Kolean CPA (Age 60)
VP, CFO & Secretary
Comp: $453.22k
Mr. Jarrod Longcor (Age 51)
Chief Operating Officer
Comp: $625.32k
Mr. Darrell Shane Lea (Age 51)
Chief Commercial Officer
Dr. Andrei Shustov M.D. (Age 53)
Senior Vice President of Medical

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings or view top-rated stocks.
What is Cellectar Biosciences' stock price target for 2024?: 2 equities research analysts have issued 12-month target prices for Cellectar Biosciences' stock. Their CLRB share price targets range from $12.00 to $28.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 557.9% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.
How have CLRB shares performed in 2024?: Cellectar Biosciences' stock was trading at $2.77 on January 1st, 2024. Since then, CLRB stock has increased by 9.7% and is now trading at $3.04.
View the best growth stocks for 2024 here.
Are investors shorting Cellectar Biosciences?: Cellectar Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,530,000 shares, an increase of 34.6% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 1.4 days. Approximately 8.7% of the company's stock are sold short.
View Cellectar Biosciences' Short Interest.
When is Cellectar Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLRB earnings forecast.

How were Cellectar Biosciences' earnings last quarter?: Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.10.
When did Cellectar Biosciences' stock split?: Cellectar Biosciences's stock reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Cellectar Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).
How do I buy shares of Cellectar Biosciences?: Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial